The Lupus Research Alliance announced, in collaboration with Lupus Therapeutics, that it has launched a new study to accelerate research for novel treatments in patients with systemic lupus erythematosus. In the new observational Lupus Landmark Study, researchers plan to recruit 3,500 patients with lupus over the course of 5 years in an effort to propel the development of personalized therapeutics for this patient population. As part of the Lupus Nexus—a patient-centered lupus registry and biorepository—the new study is expected to help advance the understanding of the disease, stratify patients by their disease pathologies, encourage global collaboration and information exchanges, boost the collection of more diverse patient data, and provide patients with a voice regarding lupus initiatives. Through the Lupus Nexus, researchers hope to use deidentified patient data from the study to detect potential new biomarkers and therapeutic approaches for lupus. “[W]ith the Lupus Landmark Study and the Lupus Nexus, we’ll not only have better data, but we’ll be able to better collaborate to find more treatments that will enable more personalized care for [patients] with lupus,” concluded lead investigator S. Sam Lim, MD, MPH, Clinical Assistant Professor of Medicine in the Division of Rheumatology at the School of Medicine and Associate Professor of Epidemiology at the Rollins School of Public Health at Emory University as well as Chief of Rheumatology at Grady Memorial Hospital.
May 31, 2023